lactic acid has been researched along with Cardiomyopathies, Primary in 37 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The changes in endothelium-derived vascular regulatory factors during dobutamine (DOB)-induced myocardial ischemia (MI) were investigated in 21 patients with Kawasaki disease aged from 11 months to 18 years." | 7.70 | Changes in endothelium-derived vascular regulatory factors during dobutamine-stress-induced silent myocardial ischemia in patients with Kawasaki disease. ( Hino, Y; Katsube, Y; Ogawa, S; Ohkubo, T, 1999) |
| "Levosimendan was effective in improving heart function." | 5.51 | Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy. ( Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D, 2019) |
| "The changes in endothelium-derived vascular regulatory factors during dobutamine (DOB)-induced myocardial ischemia (MI) were investigated in 21 patients with Kawasaki disease aged from 11 months to 18 years." | 3.70 | Changes in endothelium-derived vascular regulatory factors during dobutamine-stress-induced silent myocardial ischemia in patients with Kawasaki disease. ( Hino, Y; Katsube, Y; Ogawa, S; Ohkubo, T, 1999) |
| "Flux through the adenosine production and degradation pathways is transiently increased during hypoxia." | 3.68 | Interstitial purine metabolites and lactate during regional myocardial hypoxia. ( Downey, HF; Van Wylen, DG; Williams, AG, 1993) |
| "The new definitions of sepsis and septic shock reflect the inadequate sensitivity, specify, and lack of prognostication of systemic inflammatory response syndrome criteria." | 2.55 | Sepsis and Septic Shock Strategies. ( Armstrong, BA; Betzold, RD; May, AK, 2017) |
| "Levosimendan was effective in improving heart function." | 1.51 | Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy. ( Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D, 2019) |
| "Background Sepsis is the overwhelming host response to infection leading to shock and multiple organ dysfunction." | 1.51 | Myocardial Strain and Cardiac Output are Preferable Measurements for Cardiac Dysfunction and Can Predict Mortality in Septic Mice. ( Bauer, M; Bonios, MJ; de Lucia, C; Drosatos, K; Hoffman, M; Koch, WJ; Kyriazis, ID; Lucchese, AM; Piedepalumbo, M; Schulze, PC, 2019) |
| "Hemolysis is common in all extracorporeal circuits as evident by the elevated plasma free hemoglobin (PFHb) level." | 1.42 | Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. ( Caldeira, C; Camporesi, EM; Mangar, D; Mirsaeidi, M; Omar, HR; Socias, S; Sprenker, C, 2015) |
| "Therapy refractory cardiogenic shock is associated with dismal outcome." | 1.40 | Percutaneous extracorporeal life support for patients in therapy refractory cardiogenic shock: initial results of an interdisciplinary team. ( Born, F; Fischer, M; Guenther, S; Hagl, C; Khaladj, N; Massberg, S; Peterss, S; Pichlmaier, M; Sattler, S; Theiss, HD, 2014) |
| "High output cardiac failure is rare in MD patients and is related to myocardial abnormalities and hyperlactacidemia." | 1.40 | Refractory high output heart failure in a patient with primary mitochondrial respiratory chain disease. ( Horii, M; Kamon, D; Kawakami, R; Nakagawa, H; Nakano, T; Okayama, S; Onoue, K; Saito, Y; Sakaguchi, Y; Takemura, G; Uemura, S, 2014) |
| "Glycine has been shown to participate in protection from hypoxia/reoxygenation injury." | 1.39 | Effects of glycine supplementation on myocardial damage and cardiac function after severe burn. ( Liang, GP; Lv, SJ; Peng, X; Wan, QX; Wang, L; Yan, H; Zhang, Y, 2013) |
| "Myocardial ischemia has been suggested as a possible cause." | 1.31 | Evidence of functional myocardial ischemia associated with myocardial dysfunction in brain-dead pigs. ( de Talancé, N; Devaux, Y; Grosjean, S; Mairose, P; Mertes, PM; Seguin, C; Siaghy, EM; Ungureanu-Longrois, D; Zannad, F, 2001) |
| "Fifteen consecutive patients with septic shock and six mechanically ventilated patients without septic shock." | 1.30 | Myocardial cell injury in septic shock. ( Bellomo, R; Tsamitros, M; Turner, A, 1999) |
| "In this acute endotoxic shock model, CWH at 3 Uhr improved cardiac performance and decreased pulmonary vasoconstriction." | 1.30 | Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. ( Pauwels, D; Rogiers, P; Smail, N; Vincent, JL; Zhang, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.22) | 18.7374 |
| 1990's | 11 (29.73) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 11 (29.73) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraki, N | 1 |
| Tanaka, TD | 1 |
| Yoshimura, M | 1 |
| Li, L | 1 |
| Zhang, S | 1 |
| He, B | 1 |
| Chen, X | 1 |
| Zhao, Q | 1 |
| Zheng, Z | 1 |
| Ma, H | 1 |
| Zhang, X | 1 |
| Tu, F | 1 |
| Wang, X | 1 |
| Ha, T | 1 |
| Fan, M | 1 |
| Liu, L | 1 |
| Xu, J | 1 |
| Yu, K | 1 |
| Wang, R | 1 |
| Kalbfleisch, J | 1 |
| Kao, R | 1 |
| Williams, D | 1 |
| Li, C | 1 |
| Armstrong, BA | 1 |
| Betzold, RD | 1 |
| May, AK | 1 |
| Sommerville, EW | 1 |
| Zhou, XL | 1 |
| Oláhová, M | 1 |
| Jenkins, J | 1 |
| Euro, L | 1 |
| Konovalova, S | 1 |
| Hilander, T | 1 |
| Pyle, A | 1 |
| He, L | 1 |
| Habeebu, S | 1 |
| Saunders, C | 1 |
| Kelsey, A | 1 |
| Morris, AAM | 1 |
| McFarland, R | 1 |
| Suomalainen, A | 1 |
| Gorman, GS | 1 |
| Wang, ED | 1 |
| Thiffault, I | 1 |
| Tyynismaa, H | 1 |
| Taylor, RW | 1 |
| Sumanaru, D | 1 |
| Josseran, L | 1 |
| Essid, A | 1 |
| Mbieleu, B | 1 |
| Haegy, I | 1 |
| Bergounioux, J | 1 |
| Hoffman, M | 1 |
| Kyriazis, ID | 1 |
| Lucchese, AM | 1 |
| de Lucia, C | 1 |
| Piedepalumbo, M | 1 |
| Bauer, M | 1 |
| Schulze, PC | 1 |
| Bonios, MJ | 1 |
| Koch, WJ | 1 |
| Drosatos, K | 1 |
| Guenther, S | 1 |
| Theiss, HD | 1 |
| Fischer, M | 1 |
| Sattler, S | 1 |
| Peterss, S | 1 |
| Born, F | 1 |
| Pichlmaier, M | 1 |
| Massberg, S | 1 |
| Hagl, C | 1 |
| Khaladj, N | 1 |
| Nakagawa, H | 1 |
| Okayama, S | 1 |
| Kamon, D | 1 |
| Nakano, T | 1 |
| Onoue, K | 1 |
| Kawakami, R | 1 |
| Horii, M | 1 |
| Sakaguchi, Y | 1 |
| Uemura, S | 1 |
| Takemura, G | 2 |
| Saito, Y | 1 |
| Omar, HR | 1 |
| Mirsaeidi, M | 1 |
| Socias, S | 1 |
| Sprenker, C | 1 |
| Caldeira, C | 1 |
| Camporesi, EM | 1 |
| Mangar, D | 1 |
| Uemura, T | 1 |
| Yamamuro, M | 1 |
| Kaikita, K | 1 |
| Takashio, S | 1 |
| Utsunomiya, D | 1 |
| Hirakawa, K | 1 |
| Nakayama, M | 1 |
| Sakamoto, K | 1 |
| Yamamoto, E | 1 |
| Tsujita, K | 1 |
| Kojima, S | 1 |
| Hokimoto, S | 1 |
| Yamashita, Y | 1 |
| Ogawa, H | 1 |
| Zhang, Y | 1 |
| Lv, SJ | 1 |
| Yan, H | 1 |
| Wang, L | 1 |
| Liang, GP | 1 |
| Wan, QX | 1 |
| Peng, X | 1 |
| Yoon, YA | 1 |
| Lee, DH | 1 |
| Ki, CS | 1 |
| Lee, SY | 1 |
| Kim, JW | 1 |
| Lee, YW | 1 |
| Park, HD | 1 |
| Wang, N | 1 |
| Minatoguchi, S | 1 |
| Arai, M | 1 |
| Uno, Y | 1 |
| Nishida, Y | 1 |
| Hashimoto, K | 1 |
| Xue-Hai, C | 1 |
| Fukuda, K | 1 |
| Akao, S | 1 |
| Fujiwara, H | 1 |
| Kirkeby-Garstad, I | 1 |
| Stenseth, R | 1 |
| Sellevold, OF | 1 |
| Maxwell, MS | 1 |
| DeAnda, A | 1 |
| Vickery, R | 1 |
| Gaba, DM | 1 |
| Onorati, F | 1 |
| Cristodoro, L | 1 |
| Caroleo, S | 1 |
| Esposito, A | 1 |
| Amantea, B | 1 |
| Santangelo, E | 1 |
| Renzulli, A | 1 |
| Zhao, G | 1 |
| Jeoung, NH | 1 |
| Burgess, SC | 1 |
| Rosaaen-Stowe, KA | 1 |
| Inagaki, T | 1 |
| Latif, S | 1 |
| Shelton, JM | 1 |
| McAnally, J | 1 |
| Bassel-Duby, R | 1 |
| Harris, RA | 1 |
| Richardson, JA | 1 |
| Kliewer, SA | 1 |
| Schelbert, HR | 1 |
| Benson, L | 1 |
| Schwaiger, M | 1 |
| Perloff, J | 1 |
| Curtius, JM | 1 |
| Stechern, V | 1 |
| Kuhn, H | 1 |
| Loogen, F | 1 |
| Sonett, J | 1 |
| Pagani, FD | 1 |
| Baker, LS | 1 |
| Honeyman, T | 1 |
| Hsi, C | 1 |
| Knox, M | 1 |
| Cronin, C | 1 |
| Landow, L | 1 |
| Visner, MS | 1 |
| Van Wylen, DG | 1 |
| Williams, AG | 1 |
| Downey, HF | 1 |
| Hurley, J | 1 |
| McDonagh, P | 1 |
| Cahill, M | 1 |
| White, M | 1 |
| Luke, D | 1 |
| McGovern, E | 1 |
| Phelan, D | 1 |
| Dionisi-Vici, C | 1 |
| Ruitenbeek, W | 1 |
| Fariello, G | 1 |
| Bentlage, H | 1 |
| Wanders, RJ | 1 |
| Schägger, H | 1 |
| Bosman, C | 1 |
| Piantadosi, C | 1 |
| Sabetta, G | 1 |
| Bertini, E | 1 |
| Stierle, U | 1 |
| Giannitsis, E | 1 |
| Sheikhzadeh, A | 1 |
| Potratz, J | 1 |
| Seth, SD | 2 |
| Maulik, M | 1 |
| Katiyar, CK | 1 |
| Maulik, SK | 1 |
| Wolfhard, U | 1 |
| Knocks, M | 1 |
| Splittgerber, FH | 1 |
| Sack, S | 1 |
| Piotrowski, JA | 1 |
| Günnicker, M | 1 |
| Hino, Y | 1 |
| Ohkubo, T | 1 |
| Katsube, Y | 1 |
| Ogawa, S | 1 |
| Turner, A | 1 |
| Tsamitros, M | 1 |
| Bellomo, R | 1 |
| Rogiers, P | 1 |
| Zhang, H | 1 |
| Smail, N | 1 |
| Pauwels, D | 1 |
| Vincent, JL | 1 |
| Seguin, C | 1 |
| Devaux, Y | 1 |
| Grosjean, S | 1 |
| Siaghy, EM | 1 |
| Mairose, P | 1 |
| Zannad, F | 1 |
| de Talancé, N | 1 |
| Ungureanu-Longrois, D | 1 |
| Mertes, PM | 1 |
| Canver, CC | 1 |
| Lewis, W | 1 |
| Haase, CP | 1 |
| Raidel, SM | 1 |
| Russ, RB | 1 |
| Sutliff, RL | 1 |
| Hoit, BD | 1 |
| Samarel, AM | 1 |
| Boyle, WA | 1 |
| Segel, LD | 1 |
| Bünger, R | 1 |
| Swindall, B | 1 |
| Brodie, D | 1 |
| Zdunek, D | 1 |
| Stiegler, H | 1 |
| Walter, G | 1 |
| Ruddy, TD | 1 |
| Shumak, SL | 1 |
| Liu, PP | 1 |
| Barnie, A | 1 |
| Seawright, SJ | 1 |
| McLaughlin, PR | 1 |
| Zinman, B | 1 |
| Choudhury, S | 1 |
| Manchanda, SC | 1 |
| Gupta, MP | 1 |
| Gupta, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mortality Due to Septic Shock Associated With Thrombocytopenia in the Intensive Care Unit[NCT03617965] | 350 participants (Anticipated) | Observational | 2018-08-15 | Active, not recruiting | |||
| A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECM[NCT02940327] | 24 participants (Actual) | Observational | 2016-02-19 | Completed | |||
| Study of Impact of Three Body Positioning Strategies in the Drainage Fluids in the Immediate Postoperative Period in Patients After Coronary Artery Bypass Surgery[NCT02525289] | Phase 1 | 101 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Energy MEtabolism of Septic Heart.[NCT05202938] | 32 participants (Anticipated) | Observational | 2022-07-21 | Recruiting | |||
| Impact of a Continuous Dialysis Technique Associated With Adsorption Capacity Membranes in Patients With Sepsis Associated - Acute Kidney Injury.[NCT01790620] | 110 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | ml (Mean) |
|---|---|
| 7+ Days | 289.6 |
| <7 Days | 479.2 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.5 |
| <7 Days | 0.84 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.02 |
| <7 Days | 0.38 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.01 |
| <7 Days | 0.40 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.29 |
| <7 Days | 0.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.72 |
| <7 Days | 0.59 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percent change (Mean) |
|---|---|
| 7+ Days | 1.90 |
| <7 Days | 1.13 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.56 |
| <7 Days | 0.6 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.11 |
| <7 Days | 0.64 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.73 |
| <7 Days | 0.4 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.55 |
| <7 Days | 0.93 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 8.7 |
| <7 Days | 4.65 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.2 |
| <7 Days | 2.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 7.34 |
| <7 Days | 1.89 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.26 |
| <7 Days | 0.92 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.31 |
| <7 Days | 1.9 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.64 |
| <7 Days | 112.07 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.25 |
| <7 Days | 110.23 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 114.30 |
| <7 Days | 109.43 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.56 |
| <7 Days | 113.08 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.90 |
| <7 Days | 109.89 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: baseline
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 151.5 |
| <7 Days | 145.4 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: > 7 days or did not survive to discharge
| Intervention | hours (Median) |
|---|---|
| 7+ Days | 292 |
| <7 Days | 80 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 7.89 |
| <7 Days | 6.96 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 9.54 |
| <7 Days | 7.44 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 3.71 |
| <7 Days | 3.11 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 2.13 |
| <7 Days | 1.81 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 5.51 |
| <7 Days | 5.88 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | Participants (Count of Participants) |
|---|---|
| 7+ Days | 10 |
| <7 Days | 10 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: >7 days or did not survive to discharge
| Intervention | participants (Number) |
|---|---|
| 7+ Days | 3 |
| <7 Days | 0 |
2 reviews available for lactic acid and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Sepsis and Septic Shock Strategies.
Topics: Anti-Bacterial Agents; Arterial Pressure; Cardiomyopathies; Central Venous Pressure; Critical Care; | 2017 |
Myocardial ischemia in generalized coronary artery-left ventricular microfistulae.
Topics: Aged; Cardiac Catheterization; Cardiomyopathies; Coronary Angiography; Coronary Disease; Echocardiog | 1998 |
1 trial available for lactic acid and Cardiomyopathies, Primary
| Article | Year |
|---|---|
The haemodynamic effect of prophylactic peri-operative dopexamine in coronary artery bypass patients.
Topics: Adult; Cardiomyopathies; Dopamine; Female; Heart Rate; Hemodynamics; Humans; Intraoperative Care; La | 1995 |
34 other studies available for lactic acid and Cardiomyopathies, Primary
| Article | Year |
|---|---|
A Man With Left Ventricular Hypertrophy.
Topics: Adult; Atrophy; Cardiomyopathies; Cerebellar Diseases; Cognitive Dysfunction; Echocardiography; Gluc | 2022 |
Retrospective Study of Risk Factors for Myocardial Damage in Patients With Critical Coronavirus Disease 2019 in Wuhan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; C-Reactive Protein; Cardiomyopathies; China; Coronaviru | 2020 |
Enhanced Glycolytic Metabolism Contributes to Cardiac Dysfunction in Polymicrobial Sepsis.
Topics: Animals; Cardiomyopathies; Cytokines; Deoxyglucose; Disease Models, Animal; Glycolysis; Heart; Hexok | 2017 |
Instability of the mitochondrial alanyl-tRNA synthetase underlies fatal infantile-onset cardiomyopathy.
Topics: Alanine-tRNA Ligase; Cardiomyopathies; Diseases in Twins; Enzyme Stability; Fibroblasts; Genes, Rece | 2019 |
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
Topics: Acute Disease; Adult; Cardiomyopathies; Cardiotonic Agents; Heart Failure; Humans; Lactic Acid; Male | 2019 |
Myocardial Strain and Cardiac Output are Preferable Measurements for Cardiac Dysfunction and Can Predict Mortality in Septic Mice.
Topics: Animals; Biomarkers; Cardiac Output; Cardiomyopathies; Cytokines; Disease Models, Animal; Disease Pr | 2019 |
Percutaneous extracorporeal life support for patients in therapy refractory cardiogenic shock: initial results of an interdisciplinary team.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiomyopathies; E | 2014 |
Refractory high output heart failure in a patient with primary mitochondrial respiratory chain disease.
Topics: Adult; Cardiac Output, High; Cardiomyopathies; Heart Failure; Hemodiafiltration; Humans; Lactic Acid | 2014 |
Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support.
Topics: Aged; Biomarkers; Blood Transfusion; Cardiomyopathies; Extracorporeal Membrane Oxygenation; Female; | 2015 |
Late gadolinium enhancement on cardiac magnetic resonance predicts coronary vasomotor abnormality and myocardial lactate production in patients with chronic heart failure.
Topics: Acetylcholine; Adult; Aged; Biomarkers; Blood Flow Velocity; Cardiomyopathies; Chi-Square Distributi | 2016 |
Effects of glycine supplementation on myocardial damage and cardiac function after severe burn.
Topics: Adenosine Triphosphate; Alanine; Analysis of Variance; Animals; Aspartate Aminotransferases; Biomark | 2013 |
SLC22A5 mutations in a patient with systemic primary carnitine deficiency: the first Korean case confirmed by biochemical and molecular investigation.
Topics: Ammonia; Base Sequence; Cardiomyopathies; Carnitine; Humans; Hyperammonemia; Infant, Newborn; Lactic | 2012 |
Sheng-Mai-San is protective against post-ischemic myocardial dysfunction in rats through its opening of the mitochondrial KATP channels.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathies; Cardiotonic Agents; Drug Combinations; Drugs, Chi | 2002 |
Post-operative myocardial dysfunction does not affect the physiological response to early mobilization after coronary artery bypass grafting.
Topics: Aged; Aortic Valve; Cardiomyopathies; Chlorides; Coronary Artery Bypass; Early Ambulation; Electroca | 2005 |
Lactate extraction and myocardial damage after countershock at different energy levels.
Topics: Anesthetics, Inhalation; Animals; Cardiomyopathies; Differential Threshold; Disease Models, Animal; | 1988 |
Troponin I and lactate from coronary sinus predict cardiac complications after myocardial revascularization.
Topics: Aged; Cardiomyopathies; Coronary Vessels; Female; Heart Diseases; Humans; Lactic Acid; Male; Middle | 2007 |
Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy.
Topics: Aging; Animals; Blotting, Western; Calcineurin; Cardiomyopathies; Humans; Lactic Acid; Mice; Mice, T | 2008 |
Positron emission tomography. The technique and its applications to the study of the cardiovascular system.
Topics: Acetates; Amino Acids; Blood Glucose; Cardiomyopathies; Child; Coronary Circulation; Energy Metaboli | 1983 |
[Echocardiographic follow-up in latent cardiomyopathy].
Topics: Bundle-Branch Block; Cardiac Volume; Cardiomyopathies; Echocardiography; Electrocardiography; Exerci | 1984 |
Correction of intramyocardial hypercarbic acidosis with sodium bicarbonate.
Topics: Acidosis; Animals; Carbon Dioxide; Cardiomyopathies; Coronary Circulation; Dogs; Extracellular Space | 1994 |
Interstitial purine metabolites and lactate during regional myocardial hypoxia.
Topics: Adenosine; Animals; Cardiomyopathies; Coronary Circulation; Dialysis; Dogs; Extracellular Space; Fem | 1993 |
New familial mitochondrial encephalopathy with macrocephaly, cardiomyopathy, and complex I deficiency.
Topics: Cardiomyopathies; Electrophoresis, Gel, Two-Dimensional; Family Health; Fatal Outcome; Fibroblasts; | 1997 |
Role of Lipistat in protection against isoproterenol induced myocardial necrosis in rats: a biochemical and histopathological study.
Topics: Adenosine Triphosphate; Adrenergic beta-Agonists; Animals; Cardiomyopathies; Fat Necrosis; Female; H | 1998 |
Effects of defibrillator implantation testing on myocardial metabolism.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathies; Coronary Disease; Defibrillators, Implant | 1999 |
Changes in endothelium-derived vascular regulatory factors during dobutamine-stress-induced silent myocardial ischemia in patients with Kawasaki disease.
Topics: Adolescent; Calcinosis; Cardiomyopathies; Child; Child, Preschool; Coronary Angiography; Dobutamine; | 1999 |
Myocardial cell injury in septic shock.
Topics: Adult; Aged; APACHE; Cardiomyopathies; Case-Control Studies; Catecholamines; Creatine Kinase; Dose-R | 1999 |
Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock.
Topics: Analysis of Variance; Animals; Cardiomyopathies; Dogs; Hemodynamics; Hemofiltration; Immunotherapy; | 1999 |
Evidence of functional myocardial ischemia associated with myocardial dysfunction in brain-dead pigs.
Topics: Adenosine; Animals; Blood Flow Velocity; Blood Gas Analysis; Blood Pressure; Brain Death; Cardiac Ou | 2001 |
Serum lactates are not predictive of heart failure severity in status I cardiac transplant candidates.
Topics: Biomarkers; Cardiac Catheterization; Cardiomyopathies; Critical Care; Heart Failure; Heart Transplan | 2001 |
Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2001 |
Attenuation of vasopressin-mediated coronary constriction and myocardial depression in the hypoxic heart.
Topics: Animals; Arginine Vasopressin; Cardiomyopathies; Coronary Circulation; Coronary Vessels; Heart; Hypo | 1990 |
Pyruvate attenuation of hypoxia damage in isolated working guinea-pig heart.
Topics: Animals; Carbon Dioxide; Cardiomyopathies; Deoxyglucose; Fatty Acids; Glucose; Guinea Pigs; Heart; H | 1986 |
The relationship of cardiac diastolic dysfunction to concurrent hormonal and metabolic status in type I diabetes mellitus.
Topics: Adult; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Type 1; Diastole; Epinephrine; Female; Gl | 1988 |
Alterations in isoproterenol-induced cardiac metabolic changes by perhexiline.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathies; Female; Glycogen; Isoproterenol; L-Lactate Dehydr | 1985 |